Open AccessCarboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: A Preliminary Report of a Phase I Dose Escalation Trial from the Carolina Conformal Therapy Consortium
Author(s) -
Socinski M. A.,
Marks L.B.,
Garst J.,
Sibley G.S.,
Blackstock W.,
Turrisi A.,
Herndon J.,
Zhou S.,
Anscher M.,
Crawford J.,
Shafman T.,
Rosenman J.
Publication year - 2001
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.6-suppl_1-20
Subject(s) - carboplatin , medicine , vinorelbine , radiation therapy , oncology , paclitaxel , toxicity , chemotherapy , urology , cisplatin
The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB‐IIIB non‐small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclitaxel or carboplatin plus vinorelbine. Data from the early stages of this parallel phase I study show that the two induction regimens are similar in toxicity and that both induce partial responses in 45% of patients. Both regimens can be followed by conformal radiotherapy using an accelerated hyperfractionated schedule to a dose of at least 80 Gy without experiencing unacceptable toxicity. Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached.